VPTDF - Ventripoint Collaborates with GE Healthcare to Bring More Functionality to its Cardiac Ultrasound Devices
(TheNewswire)
Toronto, Ontario - The Newswire - April 27, 2021 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT ) ( OTC:VPTDF) announces the Company hasentered into a collaboration with GE Healthcare.
Ventripoint has been added as an innovator under GEHealthcare’s Edison Developer Program, which helps healthcareproviders gain access to market-ready applications. As an
innovator under this program, our installed base willbe enhanced and will drive
Ventripoint’s commercial growth worldwide byaccessing GE Healthcare’s global channel.
“ We are delighted to partnerwith GE Healthcare to work towards bringing our cardiac analysis toolsto their existing customer base of cardiologists,” stated Dr. GeorgeAdams, Executive-Chairman of Ventripoint.
The collaboration between GE Healthcare and Ventripointoffers the potential to enable the medical technology company’sglobal customers to leverage the advanced 3D image analysis tools fromthe Ventripoint software applications for studies obtained using GEHealthcare’s suite of Vivid cardiac ultrasound products.
“We are excited to offer the opportunity to partnerwith third parties, to widen their market footprint while alsopotentially bringing more functionality for our users,” said KristinMcLeod, Digital Manager, Cardiovascular Ultrasound, GEHealthcare
For more information on the Ventripoint 3D softwareanalysis application, please refer to the Ventripoint website: www.ventripoint.com .
About GE Healthcare
GE Healthcare is the $18 billion healthcare business ofGE (NYSE: GE). As a leading global medical technology, pharmaceuticaldiagnostics and digital solutions innovator, GE Healthcare enablesclinicians to make faster, more informed decisions through intelligentdevices, data analytics, applications and services, supported by itsEdison intelligence platform. With over 100 years of healthcareindustry experience and around 50,000 employees globally, the companyoperates at the center of an ecosystem working toward precisionhealth, digitizing healthcare, helping drive productivity and improveoutcomes for patients, providers, health systems and researchersaround the world.
Follow us on Facebook, LinkedIn, Twitter, and Insightsfor the latest news, or visit our website www.gehealthcare.com formore information.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in theapplication of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall of Ventripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada.
For further information, please contact:
Mr. Jonathan Robinson
Email: JRobinson@oakhillfinancial.ca
Phone: (416)669-1001?????????????????????????????????????? ???
Or
Mr. Anthony Allocca
Email: aa@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release containsforward-looking statements and forward-looking information within themeaning of applicable securities laws. The use of any of the words"expect", "anticipate", "continue","estimate", "objective", "ongoing","may", "will", "project","should", "believe", "plans","intends'' and similar expressions are intended to identifyforward-looking information or statements. The forward-lookingstatements and information are based on certain key expectations andassumptions made by the Company. Although the Company believes thatthe expectations and assumptions on which such forward-lookingstatements and information are based are reasonable, undue relianceshould not be placed on the forward-looking statements and informationbecause the Company can give no assurance that they will prove to becorrect.
Since forward-looking statements andinformation address future events and conditions, by their very naturethey involve inherent risks and uncertainties. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks. Factors which could materially affect suchforward-looking information are described in the risk factors in theCompany's most recent annual management's discussion and analysis thatis available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoinglist of factors is not exhaustive. The forward-looking statementsincluded in this news release are expressly qualified by thiscautionary statement. The forward-looking statements and informationcontained in this news release are made as of the date hereof and theCompany undertakes no obligation to update publicly or revise anyforward-looking statements or information, whether as a result of newinformation, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.